In this issue:
LLV during entecavir monotherapy increases HCC risk
The importance of SVR in HCV/HIV-coinfection
Interferon stimulates HCV dsRNA
Ledipasvir/sofosbuvir in adolescents with HCV GT1
HBV reactivation risk when treating haematological malignancies
Glecaprevir + pibrentasvir in HCV GT1 after DAA failure
Epigenetic regulation of HBV transcription and host-HBV interaction
SCARB1 variants modulate HCV replication cycle and viral load
TNFα inhibits HCV viral growth and spread
Glecaprevir + pibrentasvir shows promise in HCV GT1–6
Please login below to download this issue (PDF)